# Best Peptides for Muscle Growth: Evidence & WADA (2026)

> An evidence-graded review of the peptides marketed for muscle growth and lean mass — follistatin, CJC-1295, ipamorelin, MGF and IGF-1 LR3. The honest 2026 verdict: no peptide has Grade A human muscle-outcome data, and every one is prohibited in sport by WADA.

*Published 2026-07-01 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The honest verdict
No peptide has Grade A (randomized controlled trial) human evidence for building muscle or lean mass in healthy adults. The strongest case in the class is **follistatin**, graded **B** — but only as AAV gene therapy in muscle disease, not the injectable peptide (which is D). **CJC-1295 with DAC** and **ipamorelin** are B on biomarker data only (they raise GH/IGF-1 but no trial measured muscle); **MGF** is C/D (human expression data, no intervention trial); **IGF-1 LR3** is C/D and the highest-risk option. Every one is prohibited in sport by WADA at all times.[1](https://peptidevox.com/#r1)[7](https://peptidevox.com/#r7)[25](https://peptidevox.com/#r25)

"Muscle-building peptides" is a marketing category, not a recognized therapeutic class. None of the peptides below is an FDA-approved drug for building muscle in healthy adults, and most are sold only as research chemicals not for human use. The demand is enormous and so is the hype — but the evidence needs to be read with discipline, separating what a hormone does on a lab report from what actually happens to muscle.

*This article is informational and editorial content only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. The peptides discussed are largely unapproved drugs; none is FDA-approved for muscle building. Doses are reported strictly as seen in the literature, never as a recommendation. Every peptide here is prohibited in sport at all times by the World Anti-Doping Agency — a research or supplement label confers no exemption.[25](https://peptidevox.com/#r25)*

## What is the honest state of the evidence in 2026?

The headline is uncomfortable for the category: no peptide has Grade A human evidence for building muscle or lean mass in healthy adults. The entire field rests on a mix of human trials that prove a biomarker moves (GH and IGF-1 rise) but never measured muscle, small open-label gene-therapy trials in muscle-wasting disease, and animal and cell-culture data extrapolated — often aggressively — into physique claims.[7](https://peptidevox.com/#r7)[1](https://peptidevox.com/#r1) The gap between raising an anabolic hormone on a lab report and making a healthy adult bigger, leaner and stronger is exactly where the marketing lives, and it is mostly unproven.

The most instructive human data point is not even one of the peptides below. The closest thing to a positive lean-mass trial in this space is the oral ghrelin mimetic MK-677 (ibutamoren), where a two-year RCT in older adults raised GH and IGF-1 to young-adult levels and increased fat-free mass — yet produced no gain in strength or function and worsened insulin sensitivity and fasting glucose.[23](https://peptidevox.com/#r23) That result is the template for the whole field: the number on the scan can change while the thing you actually care about does not. You can read the trial record at [PubMed Central (PMC2757071)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2757071/).

## How might these peptides help — and where does the logic break?

Skeletal-muscle hypertrophy is governed by the balance between anabolic drivers (mechanical loading driving mTOR and protein synthesis; IGF-1 driving the PI3K-Akt-mTOR axis; satellite-cell activation) and catabolic brakes — chiefly the TGF-beta-family ligand myostatin, signaling through ActRIIB to suppress growth.[3](https://peptidevox.com/#r3) The peptides marketed for muscle act on three of these nodes.

**GH secretagogues (CJC-1295 with DAC, ipamorelin)** push the body to release its own growth hormone, which drives hepatic and local IGF-1, the principal anabolic effector. CJC-1295 with DAC is a long-acting GHRH-receptor agonist; ipamorelin is a selective ghrelin/GHS-R1a agonist that also blunts somatostatin.[7](https://peptidevox.com/#r7)[10](https://peptidevox.com/#r10) The honest caveat: in healthy adults the IGF-1 negative-feedback loop caps the response, and raising GH/IGF-1 has not been shown to translate into muscle in this class. **IGF-1 analogs (IGF-1 LR3) and local splice variants (MGF/IGF-1Ec)** try to deliver the effector directly — LR3 by evading the binding proteins that sequester roughly 99 percent of circulating IGF-1, MGF as a mechano-sensitive variant thought to kick-start satellite cells through a receptor that is not the IGF-1 receptor.[16](https://peptidevox.com/#r16)[15](https://peptidevox.com/#r15) **Myostatin-pathway inhibitors (follistatin)** remove the brake, trapping myostatin and activin A upstream of the receptor.[3](https://peptidevox.com/#r3) Each mechanism is biologically real; the recurring problem is that mechanism is necessary but not sufficient, and the human outcome data are largely missing.

## Which peptide has the strongest evidence for muscle growth?

  Peptides ranked by evidence for muscle growth specifically

    CandidateBest on-target evidenceHuman muscle-outcome trial?Grade

    Follistatin (FS-344)AAV gene therapy in muscle disease: increased fiber diameter + walking distance (n=6 open-label)None as a peptide; gene therapy in disease onlyB (gene therapy) / D (peptide)
    CJC-1295 with DACPhase 1 RCTs: GH 2-10x, IGF-1 1.5-3x (biomarker only)NoneB (biomarker) / C-D (muscle)
    IpamorelinHuman GH-release PK/PD; only efficacy RCT (ileus) failedNoneB (biomarker) / C-D (muscle)
    MGF / PEG-MGFHuman expression data (mRNA rises after exercise, young only); animal PEG-MGF hypertrophyNone (expression only)C/D
    IGF-1 LR3Animal potency; failed and caused fetal death in the most rigorous studyNone (zero human trials)C (animal) / D (human)

Follistatin ranks first because it is the only candidate with direct human muscle-tissue hypertrophy data — increased fiber diameter and improved 6-minute-walk distance — but exclusively via AAV gene therapy in muscle disease (n=6 open-label), not the injectable peptide sold online, which has no human trial and is Grade D.[1](https://peptidevox.com/#r1)[2](https://peptidevox.com/#r2) CJC-1295 with DAC is second on the strongest human RCT anchor in the class — but that anchor is a biomarker result (GH and IGF-1 rise), and no completed trial ever measured muscle.[7](https://peptidevox.com/#r7) Ipamorelin follows because, while it reliably releases GH in humans, its only efficacy RCT failed its primary endpoint.[12](https://peptidevox.com/#r12) MGF has genuine human expression data but no intervention trial and a mechanistically shaky injectable rationale.[13](https://peptidevox.com/#r13)[15](https://peptidevox.com/#r15) IGF-1 LR3 ranks last and highest-risk: zero human trials, disproportionate organ overgrowth in animals, and a lethal fetal-sheep signal.[18](https://peptidevox.com/#r18)

What the evidence does NOT support
That these peptides build muscle in healthy adults (no Grade A or even Grade B human muscle-outcome trial exists for any of them in healthy people); that raising GH/IGF-1 reliably adds functional muscle (MK-677 grew fat-free mass but produced no strength gain and worsened glucose over two years); that IGF-1 LR3 is a safe shortcut (no human trials, organ overgrowth, fetal death from hypoglycemia in animals); that injectable MGF replicates the repair signal (human data are expression only, and it may act intracellularly); or that the CJC-1295 + ipamorelin stack is proven for recomposition (no human RCT of the combination exists, and ipamorelin's one efficacy trial failed).[23](https://peptidevox.com/#r23)[18](https://peptidevox.com/#r18)[15](https://peptidevox.com/#r15)

## What are the safety, legal and sport considerations?

The anti-doping picture is the non-negotiable for any tested athlete: every peptide here is prohibited at all times by WADA. GH secretagogues and GH-releasing factors (CJC-1295, ipamorelin) fall under S2.2.4 (CJC-1295 named explicitly); IGF-1 analogs and MGF under S2; and follistatin and myostatin-pathway agents under S4.3, with AAV follistatin also captured under M3 gene doping.[25](https://peptidevox.com/#r25)[24](https://peptidevox.com/#r24) Strict liability applies, detection methods exist (CJC-1295 detectable 28+ days; validated LongR3-IGF-I assays), and a doping sanction is the most likely adverse outcome for a competitive athlete.

The serious safety concerns cluster by mechanism. For **IGF-1 LR3**, hypoglycemia is the dominant acute hazard — IGF-1-receptor signaling overlaps insulin's — alongside disproportionate organ growth and an epidemiology-anchored cancer concern (higher circulating IGF-1 is consistently associated with increased cancer risk in large human cohorts and meta-analysis).[20](https://peptidevox.com/#r20)[21](https://peptidevox.com/#r21)[22](https://peptidevox.com/#r22) For **follistatin**, trapping activin A removes a pro-apoptotic brake and carries a documented pro-angiogenic/pro-tumor signaling concern, with elevated serum follistatin correlating with worse outcomes in some cancers; rapid hypertrophy can also outpace tendon and ligament adaptation.[6](https://peptidevox.com/#r6) For the **GH secretagogues**, class risks include insulin resistance and glucose dysregulation, fluid retention, and arthralgia/carpal-tunnel symptoms; CJC-1295's program ended after a participant death (deemed unrelated).[8](https://peptidevox.com/#r8) And all are sold as unregulated research chemicals, adding impurity, mislabeling, under- or over-dosing and endotoxin risk independent of the pharmacology.[19](https://peptidevox.com/#r19) Dosing figures are reported in the literature strictly as information — GH secretagogues subcutaneously (CJC-1295 weekly, ipamorelin daily), while IGF-1 LR3 and MGF have no validated human dose at all.[7](https://peptidevox.com/#r7)

On legal status, none of these is FDA-approved for muscle building. CJC-1295 was rejected by the Pharmacy Compounding Advisory Committee for compounding eligibility in December 2024; ipamorelin is not on the permitted bulks list (final rule pending); and IGF-1 LR3, MGF and follistatin are unapproved research chemicals, with the only FDA-approved IGF-1 being native mecasermin for a narrow pediatric deficiency.[9](https://peptidevox.com/#r9)[26](https://peptidevox.com/#r26)[20](https://peptidevox.com/#r20)

**Bottom line.** From a functional, root-cause perspective the verdict is uncomfortable for the category: the things that most reliably build muscle — progressive resistance training, adequate protein, and sleep — are upstream of every peptide here, free, and supported by Grade A evidence. The peptides layer supraphysiologic hormonal manipulation on top, with real anti-doping and safety liabilities and, at best, Grade B biomarker or gene-therapy support. The most-hyped agents (IGF-1 LR3, injectable MGF, injectable follistatin) have the weakest human evidence and the largest safety question marks. Regulatory facts here are current as of June 2026 and should be re-verified as FDA compounding rules finalize.

---
Source: https://peptidevox.com/injuries-and-orthopedics/peptides-for-muscle-growth
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt